Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?

Canadian Journal of Cardiology

Volumn 21, Issue 2, 2005, Pages 189-193

  Al Omran, Mohammed ^a   Lindsay, Thomas F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

ACE inhibitors; Peripheral arterial disease; Risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; RAMIPRIL;

ARTERY DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; INTERMITTENT CLAUDICATION; LIMB AMPUTATION; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; RISK FACTORS;

EID: 16844366287     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
2. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982;211:249-56.
3. Hughson WG, Mann JI, Garrod A. Intermittent claudication: Prevalence and risk factors. Br Med J 1978;1:1379-81.
4. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: Its natural course. Surgery 1975;78:795-9.
5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9.
6. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985;33:13-8.
7. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331-40.
8. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1:333-9.
9. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart and legs. The Framingham study. JAMA 1972;221:661-6.
10. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 1994;140:418-30.
11. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30:50-7.
12. Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis 1981;34:261-9.
13. Holland WW, Raftery EB, McPherson P, Stone RW. A cardiovascular survey of American East Coast telephone workers. Am J Epidemiol 1967;85:61-71.
14. Hale WE, Marks RG, May FE, Moore MT, Stewart RB. Epidemiology of intermittent claudication: Evaluation of risk factors. Age Ageing 1988;17:57-60.
15. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
16. Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Use of interventional procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: A population-based study. J Vasc Surg 2003;38:289-95.
17. Dormandy JA, Rutherford RB; TransAtlantic Inter-Society Concensus (TASC) Working Group. Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:S1-296.
18. Dormandy JA, Murray GD. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131-3.
19. Malone JM, Moore WS, Goldstone J. Life expectancy following aortofemoral arterial grafting. Surgery 1977;81:551-5.
20. Hertzer NR. Clinical experience with preoperative coronary angiography. J Vasc Surg 1985;2:510-4.
21. Turnipseed WD, Berkoff HA, Belzer FO. Postoperative stroke in cardiac and peripheral vascular disease. Ann Surg 1980;192:365-8.
22. Hennerici M, Aulich A, Sandmann W, Freund HJ. Incidence of asymptomatic extracranial arterial disease. Stroke 1981;12:750-8.
23. Alexandrova NA, Gibson WC, Norris JW, Maggisano R. Carotid artery stenosis in peripheral vascular disease. J Vasc Surg 1996;23:645-9.
24. Klop RB, Eikelboom BC, Taks AC. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg 1991;5:41-5.
25. Coffman JD. Intermittent claudication - be conservative. N Engl J Med 1991;325:577-8.
26. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: Outcome and risk factors. Br Med J (Clin Res Ed) 1986;293:1137-40.
27. Kallero KS. Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography. A ten-year follow-up study. J Chronic Dis 1981;34:455-62.
28. Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication. Current results of nonoperative management. Arch Surg 1984;119:430-6.
29. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: A review. J Clin Epidemiol 1992;45:529-42.
30. Veith FJ, Gupta SK, Samson RH, et al. Progress in limb salvage by reconstructive arterial surgery combined with new or improved adjunctive procedures. Ann Surg 1981;194:386-401.
31. Griffith CD, Callum KG. Limb salvage surgery in a district general hospital: Factors affecting outcome. Ann R Coll Surg Engl 1988;70:95-8.
32. Hickey NC, Thomson IA, Shearman CP, Simms MH. Aggressive arterial reconstruction for critical lower limb ischaemia. Br J Surg 1991;78:1476-8.
33. Ouriel K, Fiore WM, Geary JE. Limb-threatening ischemia in the medically compromised patient: Amputation or revascularization? Surgery 1988;104:667-72.
34. Nehler MR, Taylor LM, Moneta GL, Porter JM. Natural history, nonoperative treatment, and functional assessment in chronic lower extremity ischemia. In: Moore WS, ed. Vascular Surgery: A Comprehensive Review. Philadelphia: WB Saunders, 1998;251-65.
35. De Wess JA, Rob CG. Autogenous vein grafts ten years later. Surgery 1962;6:775-84.
36. Banerjee AK, Pearson J, Gilliland EL, et al. A six-year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992;68:261-3.
37. Faulkner KW, House AK. Comparative survival rates in symptomatic peripheral vascular disease and colorectal cancer. Aust N Z J Surg 1981;51:152-6.
38. Cheng SW, Ting AC, Lau H, Wong J. Survival in patients with chronic lower extremity ischemia: A risk factor analysis. Ann Vasc Surg 2000;14:158-65.
39. Hooi JD, Stoffers HE, Knottnerus JA, van Ree JW. The prognosis of non-critical limb ischaemia: A systematic review of population-based evidence. Br J Gen Pract 1999;49:49-55.
40. Crawford ES, Bomberger RA, Glaeser DH, Saleh SA, Russell WL. Aortoiliac occlusive disease: Factors influencing survival and function following reconstructive operation over a twenty-five-year period. Surgery 1981;90:1055-67.
41. Szilagyi DE, Elliott JP Jr, Smith RF, Reddy DJ, McPharlin M. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg 1986;3:421-36.
42. Dormandy J, Heeck L, Vig S. The natural history of claudication: Risk to life and limb. Semin Vasc Surg 1999;12:123-37.
43. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
44. Beach KW, Brunzell JD, Strandness DE Jr. Prevalence of severe arteriosclerosis obliterans in patients with diabetes mellitus. Relation to smoking and form of therapy. Arteriosclerosis 1982;2:275-80.
45. Melton LJ III, Macken KM, Palumbo PJ, Elveback LR. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care 1980;3:650-4.
46. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
47. Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983;2:639-42.
48. Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Outcome of revascularization procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: A population-based study. J Vasc Surg 2003;38:279-88.
49. Hirsch AT, Gloviczki P, Drooz A, Lovell M, Creager MA. Mandate for creation of a national peripheral arterial disease public awareness program: An opportunity to improve cardiovascular health. J Vasc Surg 2004;39:474-81.
50. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
51. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
52. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
53. Henke PK, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: Effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004;39:357-65.
54. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther 2002;16:149-60.
55. Lonn E, Yusuf S, Dzavik V, et al; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
56. Dzau VJ, Bernstein K, Celermajer D, et al; Working Group on Tissue Angiotensin-converting enzyme, International Society of Cardiovascular Pharmacotherapy The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:1L-20L.
57. Lopez-Sendon J, Swedberg K, McMurray J, et al; Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004;25:1454-70.